OGM invests £500,000 in cleanroom expansion
06 Mar 2023
Plastic injection moulding company, Owen Greenings and Mumford (OGM), is investing £500,000 to expand the cleanroom at its factory in Oxford. The first stage of the project is due to be complete in May.
The investment will fund a 25% increase in the footprint of the existing cleanroom plus the acquisition of two new machines, a 100 tonne ARBURG and a 160 tonne KraussMaffei. This will enable OGM to run higher cavitation tooling to produce larger components and increase overall cleanroom capacity.
Paul Wightman, group managing director of Owen Greenings & Mumford (Holdings) says: “We are investing in our cleanroom facilities to accommodate new contracts and growth from our existing customers, specifically in the production of plastic injection moulded parts for orthopaedic medical devices and automated surgical equipment. Our expansion plans not only increase our injection moulding capability but also provide extra space for added value processes such as automated assembly within the cleanroom environment.”
As a result of this investment, OGM, which celebrated its 60th anniversary at the end of last year, will be expanding its team of cleanroom machine operators with up to six new roles, in addition to new staff for assembly and packing.
Wightman concludes: “This is part of a larger investment programme for OGM. Elsewhere in the factory we have built a mezzanine floor to house ultrasonic cleaning machines that will form part of an automated production cell. Total investment in our Oxford facility is likely to exceed £2million by the end of this year.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.